Immunogen, Inc. (IMGN) Posts Q1 Loss of $0.26, Sales Fall Short
Immunogen, Inc. (NASDAQ: IMGN) reported Q1 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $5.61 million.